J W B de Groot
Overview
Explore the profile of J W B de Groot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
324
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stoop T, Seelen L, van t Land F, van der Hout A, Scheepens J, Ali M, et al.
BMC Cancer
. 2025 Feb;
25(1):299.
PMID: 39972248
Background: The introduction of (m)FOLFIRINOX and gemcitabine-nab-paclitaxel has changed the perspective for patients with locally advanced pancreatic cancer (LAPC). Consequently, in experienced centres 23% of patients with LAPC undergo a...
2.
Ozkan A, Kapiteijn E, van den Bos F, Aarts M, van den Berkmortel F, Blank C, et al.
Eur J Cancer
. 2024 Dec;
216:115194.
PMID: 39732138
No abstract available.
3.
Biesma N, Graus M, Cirkel G, Besselink M, de Groot J, Koerkamp B, et al.
Eur J Surg Oncol
. 2024 Dec;
51(3):109544.
PMID: 39689462
Introduction: Adjuvant chemotherapy improves survival in patients with resected pancreatic ductal adenocarcinoma (PDAC). The decision to initiate chemotherapy involves both patient and physician factors, decision-specific criteria, and contextual considerations. This...
4.
Ozkan A, Kapiteijn E, van den Bos F, Aarts M, van den Berkmortel F, Blank C, et al.
Eur J Cancer
. 2024 Oct;
212:115056.
PMID: 39368226
Background: Adjuvant anti-PD-1 therapy improves relapse free survival in stage III melanoma, but also leads to immune-related adverse events (irAEs). Older patients are of particular interest due to comorbidities and...
5.
van Duin I, Schuiveling M, Ter Maat L, Veta M, van Eijs M, Verheijden R, et al.
Immunooncol Technol
. 2024 Jul;
24:100714.
PMID: 39045171
Background: The predictive value of tumor-infiltrating lymphocytes (TILs) in immune-related adverse event (irAE) development remains unknown, although an association between tumor immunogenicity and irAEs has been suggested. We investigated the...
6.
van der Kruijssen D, Elias S, van de Ven P, van Rooijen K, Lam-Boer J, Mol L, et al.
Ann Oncol
. 2024 Jun;
35(9):769-779.
PMID: 38852675
Background: Upfront primary tumor resection (PTR) has been associated with longer overall survival (OS) in patients with synchronous unresectable metastatic colorectal cancer (mCRC) in retrospective analyses. The aim of the...
7.
Janssen J, van Dijk B, de Joode K, Aarts M, van den Berkmortel F, Blank C, et al.
BMC Cancer
. 2024 May;
24(1):632.
PMID: 38783238
Background: Patients with irresectable stage III or metastatic melanoma presenting with poor prognostic factors are usually treated with a combination of immune checkpoint inhibitors (ICIs), consisting of ipilimumab and nivolumab....
8.
Borgers J, Burgers F, Schina A, Van Not O, van den Eertwegh A, Blank C, et al.
Pigment Cell Melanoma Res
. 2023 Aug;
37(1):15-20.
PMID: 37554041
Despite the improved survival rates of patients with advanced stage melanoma since the introduction of ICIs, many patients do not have (long-term) benefit from these treatments. There is evidence that...
9.
van Dam J, Verkolf E, Dekker E, Bonsing B, Bratlie S, Brosens L, et al.
BMC Cancer
. 2023 Aug;
23(1):728.
PMID: 37550634
Background: Surgical resection followed by adjuvant mFOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) is currently the standard of care for patients with resectable pancreatic cancer. The main concern regarding adjuvant...
10.
Egeler M, van de Poll-Franse L, Tissier R, Rogiers A, Boers-Sonderen M, van den Eertwegh A, et al.
Qual Life Res
. 2023 Apr;
32(9):2517-2525.
PMID: 37079262
Background: Checkpoint inhibitors have been shown to substantially improve the survival of patients with advanced melanoma. With this growing group of survivors treated with immunotherapies, assessing their health-state utilities is...